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Numerous factors, other than mutations in the CFTR gene, affect the phenotypic variability of cystic fibrosis (CF). With a two-
dimensional electrophoresis (2-DE) analysis of total protein expression profiles (proteomics) of CF versus non-CF cells it is possible to
obtain an integrative picture of CF cellular alterations. Through this approach, proteins that interact differently with wild type- and mutant-
CFTR can also be identified (interactomics). This can provide insight into CF pathophysiology as well as clues for novel therapeutic targets.
Additionally, protein profiling can ultimately identify novel disease markers with the potential for a CF diagnosis not based on the analysis of
CFTR gene.
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The nearly complete sequencing of the human genome
together with major technological advances in proteomics,
allowing the sensitive identification of polypeptides from
relatively small amounts of biological material paved the
way for mapping the protein composition and interactions at
the cellular and subcellular levels. Considering the abun-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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1 These authors contributed equally to this article.dance of splicing variants and post-translational modifica-
tions, there may be as many as one million human proteins
[1]. It is estimated that 1–2% of these polypeptides can be
expressed at a given time in a cell, some of them at a very
low copy number, while others occur at high abundance.
Therefore, obtaining comprehensive expression and interac-
tion maps of proteins in various cellular systems is an
enormous challenge [1].
Elucidating the protein–protein interaction maps in time
and space will be important not only for a better under-
standing of the regulatory networks of a normal cell, but
also to unmask mechanisms that are involved in the progress
of both acquired and genetic diseases [2]. This is also true
for cystic fibrosis (CF) which in spite of being a monogenic
disease, is influenced by numerous factors (e.g., modifier
genes and environmental factors), leading to highly variably
phenotypic manifestations of the disease, most of which still
incompletely understood.
Impaired biogenesis and stability accounts for the
diminished expression of mutant CFTR at the cell mem-
brane for many CF-associated mutations including theed by Elsevier B.V. All rights reserved.
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ficking defects, CFTR mutations also cause functional
impairment of this chloride (Cl) channel, leading to
defective transepithelial ionic and water transport. A num-
ber of defective regulatory interactions of CFTR with other
proteins has also been shown to occur. Complete identifi-
cation of multiprotein complexes containing the wt and
mutant (e.g., F508del) CFTR in various subcellular organ-
elles could reveal novel molecular links to downstream
effectors, signalling complexes, etc., that may be critical
determinants of CF pathogenesis at the cellular level. A
complementary, though indirect method, which could also
reveal the perturbations of cellular regulatory pathways in
CF consists in the global comparison of protein profiles of
CF and non-CF cells and organelles. Ultimately, this
approach may lead to the identification of novel disease
markers with potential for a CF diagnosis not based on the
analysis of the CFTR gene.
The ‘‘classical’’ expression proteomics involves four
major steps. First, separation of total protein spots by
two-dimensional electrophoresis (2-DE) analysis of a given
cell type, tissue or organ under one or various conditions.
Second, detection by one of the different staining methods
available (see Table 1). As much as 1000–3000 proteins
can be visualized by this approach. Third, bioinformatics
analysis is carried out aimed at producing 2-DE maps for
database comparison. Fourth, identification by Edman
sequencing or mass spectrometry (MS) of the spots of
interest.
It is important to note that the most common technol-
ogy only allows the identification of highly abundant
proteins, representing 5% to 15% of the total [1]. In
order to increase the sensitivity of the identification
technique, novel methods are being developed, namely
based on radioisotopic detection or affinity-capture for the
selective enrichment on a particular subset of proteins [3].
A more recently developed approach is cell-map proteo-
mics or interactomics, i.e., a systematic study of protein–
protein interactions, for which both biochemical andTable 1
Currently used methods for detection of proteins separated by 2-DE
Dye Detection
limits (ng)
Linear
dynamic
range
Differential
display
Quantification
Coomassie
Blue
15–30 30–250 ng Comparison of
two gels
relative
Silver
staining
1–5 1–100 ng Comparison of
two gels
relative
SyproR
Ruby
1–5 1–1000 g Comparison of
two gels
relative
Cye-dyes 2–10 10–5000 ng Comparison of
two samples
within one gel
relative
I125, I131 0.001 10 4–103 ng Comparison of
two samples
within one gel
quantitativegenetics approaches can be used and these are discussed
below.2. Basic proteomics methodology
Although the basic procedure for 2-DE (first dimension:
isoelectric focusing (IEF), second dimension: sodium
dodecyl sulphate (SDS)-polyacrilamide gel (SDS-PAGE))
was described 15 years ago [3] several improvements have
been made recently [4]. These developments concern
mainly the protein sample preparation and IEF.
2.1. Sample preparation, 2-DE
According to Rabilloud [5] and Herbert [6], the prepa-
ration of protein samples for IEF involves solubilization,
denaturation and reduction to completely dissociate protein
interactions with other macromolecules (e.g., nucleic acid
and lipids). The mostly widely used solubilization buffer
contains non-ionic detergents such as zwitterionic detergent
CHAPS, urea/thiourea, dithiothreitol (DTT) and carrier
ampholytes [5]. To minimize interferences with IEF, the
salt concentration should be less than 7 mM and that of
anionic detergents, such as SDS, should not exceed 0.1%
(w/v). Samples containing urea must not be heated over 37
jC, since it may introduce protein alterations by carbamy-
lation [7]. Solubilization should be performed in single step
to avoid protein loss and proteolysis. It is often recommen-
ded to add protease inhibitors such as phenyl methyl
sulfonyl fluoride (PMSF), Pefabloc or protease inhibitor
cocktails.
A major progress in IEF was achieved by the development
of immobilized pH gradients (IPG) [7]. IPGs are based on the
principle that the pH gradient generated by well-defined
chemicals (the immobilines) is integral part of polyacryl-
amide gel matrix. The IPG strip gels are produced at any
desired stable pH range (broad, narrow or ultra narrow)
between pH 3 and 12. Several choices of IPG strips gels with
different lengths and pH gradients are currently available
from manufacturers. The introduction of IPG in IEF in
combination with the multi-slab gel running capacity of some
SDS-PAGE units has produced significant improvements in
the reproducibility of comparative 2-DE analysis. However,
problems are still encountered in the separation of basic
proteins (8.5 to 11) and in limited reproducibility of the IEF
separation.
Although more details on protocols for 2-DE can be
found at the European Working Group on CFTR Expression
website [8], a general protocol is briefly described here.
Briefly, to produce a total protein extract, cells are lysed in a
specific buffer (7 M urea; 2 M thiourea; 4% (w/v) CHAPS;
1% (w/v) 1,4-dithioerythritol (DTE); 2% (w/v) ampholine
3.5–10.0) and this extract is loaded onto a non-linear wide-
range immobilized commercially available gradient strip
(e.g., pH 3–10). The proteins are separated according to
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total 45,000 Vh, in which the voltage is gradually increased.
The first dimension gel is then soaked into a 2% (w/v) DTE
solution to reduce thiol groups of proteins and equilibrated
in 2.5% (w/v) iodoacetamide to prevent reoxidation. The
presence of 2% (w/v) SDS in these two buffers confers the
negative charge to all proteins required so that the second
dimension separation is based solely on relative molecular
mass. Finally, the strip is applied onto an 8–16% (w/v)
gradient SDS-PAGE.
The above described protocol, adapted from Ref. [4],
allows separation and detection of proteins with a pI value
between 3 and 10 and molecular mass in the range of 14–
150 kDa. For the detection of specific proteins (e.g.,
membrane proteins, basic proteins, etc.) this standard pro-
tocol has to be optimized [9]. CFTR, for instance, is not
detected by this 2-DE protocol.
2.2. Protein detection and software analysis
The detection of proteins separated by 2-DE uses meth-
ods that have been developed for one dimensional electro-
phoresis [8,10]. The ideal method should have a low
detection threshold and a linear dynamic range from sub-
attomol to picomol quantities [1,11]. The currently used
techniques include the traditional staining using organic
dyes such as Coomassie Blue, metal ion reduction (silver
staining, now modified for subsequent MS analysis) or the
novel fluorescent dye SyproR Ruby Protein Stain (Cam-
brex, Baltimore, MD) [12] (see Table 1). These, however,
have low sensitivity and a narrow dynamic range, thus
preventing quantitative analysis of biological samples con-
taining small amounts of the relevant polypeptides. The best
available methods in terms of a wide dynamic range and
high sensitivity are based on the radioisotopic detection of
target polypeptides.
New generation of detectors are currently being devel-
oped like the multiphoton detector (MPD) [13]. MPD
measures decay of radioactive isotopes by an electron
capture mechanism, thus emitting synchronized photons
of defined energies at levels that are well below the
naturally occurring background radiation. As background
activity rarely provides synchronized photons of defined
energies, these measurements allow the detection levels of
10 attomole. The method offers substantial advantage in
terms of absolute sensitivity and dynamic range. Its major
disadvantage is biohazard associated with radioactive
samples.
To evaluate the complex protein patterns on 2-DE,
independently of the staining method, gels can be digita-
lized and the resulting images analysed by specific com-
mercially available software (PDQUEST, MELANIE or
Progenesis). The latter produce synthetic gel images (2-
DE maps), quantify individual protein spots and match spot
patterns among multiple gels, such as disease versus control
sets. Statistical analysis can be performed on groups ofprotein spots for which up- or down-regulation can be
assessed. Extensive databases of 2-DE maps are freely
available online [14].
2.3. Protein identification and characterization
MS techniques coupled database searching (ProFound
Search, MASCOT or SEQUEST) have played a crucial role
in proteomics. Matrix-associated laser desorption/ionisation
time-of-flight (MALDI-TOF-MS) is the most commonly
used MS approach to identify proteins of interest excised
from the 2-DE gels, by generation of peptide-mass finger-
printing. Peptide-mass fingerprinting involves determination
of the mass of all peptides following digestion (usually with
trypsin). Subsequent fragmentation of selected peptides
produces peptide-sequence tags that are used to search a
protein sequence in a database for its identification of
protein of interest. Importantly, MS identification should
be interpreted with caution, particularly when unknown
interacting proteins are being identified. Reliable identifica-
tion requires that the algorithm (ProFound Search or MAS-
COT) provides sufficiently high score and at least 30%
sequence coverage of the candidate interacting protein (see
below).
By using radioisotopic-labbeling it is possible to detect
proteins at the level below 10 attomole (for a 50 kDa
protein) on 2-DE gels. However, the available methods for
MS identification at that sensitivity level are time-consum-
ing and expensive. Although progress in MS in recent years
offers the ability to address complex mixtures of proteins
and its post-translational modifications (PTM), the identifi-
cation sensitivity is still in the 1–10 fentomol level (for 50 a
kDa protein). In the last 2 years the use of Fourier
transform-ion cyclotron resonance (FT-ICR) MS has in-
creased mass resolution and mass measurement accuracy,
sensitivity, and has a potential to perform multi-stage MS
experiments (MSn). Current developments demonstrate a
detection limit of approximately 30 zmol, for a protein of
f 10 kDa [15]. In the forthcoming years, progress in MS is
a necessary milestone for the identification of low abundant
proteins.
An attractive experimental approach currently under
development is MS imaging [16]. This technique will permit
profiling proteins in tissues, cells and/or subcellular com-
partments as well as identifying ions, metabolites, drugs or
other molecules [17]. Profiling of proteins in tissue sections
is performed by MALDI-TOF MS. It may provide the
spatial resolution for masses up to 100 kDa. Currently, the
resolution for protein profiling is limited by the UV-laser
diameter used in the MALDI-TOF spectrometer (f 1–100
Am, commonly 50 Am). Using secondary ion MS technique
(SIMS) the distribution of molecules < 1 kDa can be
identified [17]. The spatial resolution is in the order of
0.5–1 Am and also allows subcellular localization of ions,
metabolites, lipids, drugs, etc. The MS imaging is rapidly
becoming an instrumental technique in many areas of
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therapeutic targets.3. Interactome
It is well known that CFTR interacts with many other
proteins in the cell, some of these with a plausible important
role on CFTR folding, trafficking, and regulation of this Cl
channel. The identification of such proteins can help inte-
grate CFTR activity with other cellular processes, and
understand the pathophysiology cascades involved in CF.
Genetic and biochemical strategies have been developed to
search for protein–protein interactions, both having advan-
tages and disadvantages. With genetic screens (e.g., yeast
two-hybrid) it is possible to identify protein–protein inter-
actions that occur in the native conformation of the involved
proteins or polypeptides. However, this approach requires
that the interacting proteins or polypeptides can be
expressed and appropriately localized inside eukaryotic
cells, which is one of the major limitations of the method.
The recently developed biochemical strategies based on
pull-downs from cell extracts using purified protein as bait,
e.g., Co-immunoprecipitation (Co-IP) with appropriate con-
trols, see Ref. [10], coupled with proteomics analysis seem
to be a good choice. It is important to have in mind that all
putative protein–protein interactions should be validated, as
false positives may occur due to limitations inherent to each
binding assay [18]. One possible solution is to utilize the
tandem affinity-purification technique that has been suc-
cessful in isolating macromolecular complexes from yeast
and mammalian cells [19].
Due to the low abundance of endogenous CFTR in native
epithelia and its medium/low expression levels in heterolo-
gous systems (according to functional measurements not
more than 2000 copies of CFTR are expressed at the cell
surface of a BHK cell [20]), the recovery of CFTR by IP has
to be maximized to ensure sufficient quantities of protein
complexes for identification by MS [10].
To optimize the yield of CFTR-IP and minimize the
disruptive effect of detergents, the efficiency of the
immuno-isolation procedure has to be determined as a
function of detergent type and its concentration. One pro-
cedure to successfully solubilize CFTR from cultured cell
lines is to use a low concentration, 0.1% (v/v), of non-ionic
detergents (NP-40 or TritonX-100) to preserve protein–
protein interactions. To optimally immuno-isolate CFTR it
is imperative to screen for the highest affinity antibody (Ab)
and the affinity matrix exhibiting lowest level of non-
specific binding. Affinity isolation based on any anti-CFTR
Ab has the advantage that CFTR complexes from epithelia,
expressing the endogenous channel, can be achieved. On the
other hand, the availability of isogenic cell lines expressing
epitope-tagged versions of the wt- and mutant-CFTR allows
the utilization of highly specific, commercial anti-epitope
Abs that have a decreased probability of interfering with thebinding of interacting proteins to CFTR. Obviously, any
adverse effects of inserting an epitope tag on the function
and traffic of CFTR have to be precluded by biochemical
and functional assays before proceeding with the affinity
isolation. Considering that the Ab affinity, the type of
epitope-tag, as well as its location in CFTR could influence
the IP efficiency of the channel, the effect of all these
parameters has to be carefully examined (for a discussion on
applicability of anti-CFTR Abs, see Ref. [21]).4. Conclusion
In order to obtain an integrative picture of CF cellular
alterations versus non-CF, the total protein expression
profiles of cells stably expressing wt- and mutant-CFTR
can be analyzed using 2-DE analysis. This approach can
also lead to the identification of novel disease markers with
the potential for a CF diagnosis not based on the analysis of
CFTR gene. Additionally, it seems likely that there are other
yet to be discovered CFTR binding proteins that could play
important roles in CFTR biology and thus in CF pathophys-
iology. The ongoing development and refinement of strat-
egies for the identification of protein–protein interactions,
including 2-DE gel analysis, higher sensitivity detection and
improved MS should help in this regard. Validation of such
CFTR-interactions in vivo (namely in animal models) and
functional testing to determine how such interactions influ-
ence CFTR can ultimately provide clues for novel thera-
peutic targets for CF.References
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